Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra.

Karl Claxton1, Mark Sculpher, Chris McCabe

  • 1Centre for Health Economics, Department of Economics and Related Studies, University of York, UK. kpcl@york.ac.uk

Health Economics
|March 1, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A budget apart: the case for ringfencing medicines in the UK.

BMJ (Clinical research ed.)·2026
Same author

Investigating prognostic classifications of preexisting multiple long-term conditions for health outcomes 1 year after COVID-19 hospitalization: A UK prospective observational study.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Autism and attachment disorder symptoms in the general population: Prevalence, overlap, and burden.

Developmental child welfare·2026
Same author

Methodological Challenges of Emulating a Target Trial to Assess Effectiveness of Timing of PCSK9 Inhibitor Treatment Initiation Post Myocardial Infarction.

Pharmacoepidemiology and drug safety·2026
Same author

The future of fundamental science led by generative closed-loop artificial intelligence.

Frontiers in artificial intelligence·2026
Same author

An Overdue Denunciation of the Minimal Important Difference When Applied to Health State Values.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Lead in Drinking Water and Child Health: Evidence From Jackson, Mississippi.

Health economics·2026
Same journal

Health on the Move: The Impact of Poverty Alleviation Relocation on Healthcare Utilization in China.

Health economics·2026
Same journal

The Effects of Compulsory Licensing: A Case Study of HIV Drugs.

Health economics·2026
Same journal

Beyond Tobacco Prevention: The Effects of Tobacco 21 Laws on Young Adults' Body Weight.

Health economics·2026
Same journal

Assessing the Estimands and Estimates of Hospitalization Rates in Health Economics and Clinical Medicine.

Health economics·2026
Same journal

The Impact of Unemployment Insurance Benefit Cuts on Mental Health: Evidence From Early Pandemic Program Expirations.

Health economics·2026
See all related articles

The National Institute for Clinical Excellence (NICE) now requires probabilistic sensitivity analysis for cost-effectiveness models to improve healthcare technology assessment and decision-making under uncertainty.

Area of Science:

  • Health Economics
  • Decision Analysis
  • Health Technology Assessment

Background:

  • The National Institute for Clinical Excellence (NICE) has updated its methods guidance for technology assessment.
  • A key change mandates the use of probabilistic sensitivity analysis (PSA) in all cost-effectiveness models.

Purpose of the Study:

  • To contextualize NICE's guidance on uncertainty within broader decision-making requirements.
  • To explain the development approach for the new guidance.
  • To address the ongoing debate surrounding the role of PSA.

Main Methods:

  • Establishing decision-making requirements as the foundation for analytical guidance.
  • Identifying analytical methods and frameworks that best meet these requirements.
  • Reviewing issues and criticisms related to PSA and the NICE consultation process.

Related Experiment Videos

Main Results:

  • The guidance on uncertainty, including the PSA requirement, is justified by the nature of decisions NICE faces.
  • The paper reviews key issues and criticisms raised during the consultation.
  • Methodological challenges in characterizing decision uncertainty and informing research are identified.

Conclusions:

  • The requirement for probabilistic sensitivity analysis in NICE guidance is a reasoned response to decision-making needs.
  • Addressing methodological challenges is crucial for robust health technology assessment.
  • Further discussion is needed on characterizing uncertainty and guiding future research.